Related references
Note: Only part of the references are listed.Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management
Wojciech A. Cieslikowski et al.
BIOMEDICINES (2021)
Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer
Wojciech A. Cieslikowski et al.
CANCERS (2020)
Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility
Klaus Pantel et al.
CLINICAL CHEMISTRY (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials
Glenn Heller et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Jason D. Merker et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms
Heather J. Chalfin et al.
JOURNAL OF UROLOGY (2018)
The Epidemiology of Prostate Cancer
Claire H. Pernar et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer
Nicholas J. Vogelzang et al.
EUROPEAN UROLOGY (2017)
Prevention of Prostate Cancer Morbidity and Mortality Primary Prevention and Early Detection
Michael J. Barry et al.
MEDICAL CLINICS OF NORTH AMERICA (2017)
Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer
Jennifer Podolak et al.
ONCOTARGET (2017)
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Jose Luis Perez-Gracia et al.
CANCER TREATMENT REVIEWS (2017)
Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries
Martin C. S. Wong et al.
EUROPEAN UROLOGY (2016)
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
Matthew Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer
Tilman Todenhoefer et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients
Andra Kuskel et al.
SCIENTIFIC REPORTS (2016)
Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay
Catherine Alix-Panabieres et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2015)
Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5
Karim Fizazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial
Fred Saad et al.
LANCET ONCOLOGY (2015)
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent-Update 2013
Axel Heidenreich et al.
EUROPEAN UROLOGY (2014)
Circulating tumor cell detection in high-risk non-metastatic prostate cancer
Jasmin Loh et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
Amir Goldkorn et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Epithelial Cell Adhesion Molecule-positive Circulating Tumor Cells as Predictive Biomarker in Patients With Prostate Cancer
Robert J. Amato et al.
UROLOGY (2013)
Circulating tumor cells in prostate cancer: A potential surrogate marker of survival
Jerome Doyen et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic Factors
Oscar B. Goodman et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
Howard I. Scher et al.
LANCET ONCOLOGY (2009)
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
Steven J. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: Initial results in early prostate cancer
John W. Davis et al.
JOURNAL OF UROLOGY (2008)
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
WJ Allard et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
